| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dded61bd89f99900518597c0958b9a9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate |
2016-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7339d83e44c477e7b5257d5bcd0ff4af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_466e692f52dcde47c2f29f79b9f2a0da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85fbf9245a0bf834de5543c92127e5e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4f6c86cb7dbb18696aa3b339148bc27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa3a7c0ff172970c8c3082f5a5d16aa2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_097e2caf05f759694615aa8cb5e05a81 |
| publicationDate |
2018-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180063339-A |
| titleOfInvention |
Method for preparing ibrutinib and its intermediates |
| abstract |
The present invention provides an efficient, economical and improved method for synthesizing ibrutinib and its intermediates. The present invention includes a unique two-phase acylation reaction system that allows for easy separation of ibrutinib from the reaction mixture without the need for additional extraction and washing steps. Isolated ibrutinibs formed using the methods described herein may be useful in the preparation of ibrutinib in amorphous form. In some embodiments, the isolated ibrutinib produced by the process described herein is a homogeneous solution of DMSO and ibrutinib which can be used directly in the formation of amorphous polymorphs. In some embodiments, the isolated ibrutinib is a solid ibrutinib. Solid ibrutinib may also be used in the formation of amorphous ibrutinib. |
| priorityDate |
2015-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |